The Biosimilar Threat: Which Companies Are at Risk?

Wide-moat Amgen and Roche look the most insulated, while narrow-moat AbbVie looks the most exposed to competition from the generics of the biotech industry.

Copyright © 2019, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad
46°